Why Sarepta Therapeutics, Inc.’s (SRPT) Stock Is Up 5.62%
As of Thursday, August 06, Sarepta Therapeutics, Inc.’s SRPT share price has surged by 5.62%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Sarepta Therapeutics, Inc.’s (SRPT) Stock Is Up 5.36%
As of Monday, July 27, Sarepta Therapeutics, Inc.’s SRPT share price has surged by 5.36%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Sarepta Therapeutics, Inc.’s (SRPT) Stock Is Down 7.14%
As of Friday, July 10, Sarepta Therapeutics, Inc.’s SRPT share price has dipped by 7.14%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Which Is a Better Investment, uniQure N.V. or Sarepta Therapeutics, Inc. Stock?
Learn more about whether uniQure N.V. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Sarepta Therapeutics, Inc.’s (SRPT) Stock Is Up 5.91%
As of Thursday, July 02, Sarepta Therapeutics, Inc.’s SRPT share price has surged by 5.91%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | SRPT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,771.6 | $269.0 | 52% |
|
| Shares Out (Mil) | 105.4 | 52.3 | 63% |
|
| Institutional Ownership | 95.6% | 92.2% | 68% |
|
| Float (Mil) | 94.6 | 39.8 | 60% |
|
| Beta | 0.20 | 0.93 | 13% |
|
| Avg Daily Volume (000s) | 3,387 | 488 | 88% |
|
| Price Change (52-week) |
0.2% | 56.4% | 43% |
|
| Growth | SRPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 32.4% | 13.6% | 91% |
|
| Net Income (5yr) | (5.2%) | (10.1%) | 33% |
|
| EPS (5yr) | (0.1%) | 16.0% | 31 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.7%) | (15.6%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 8 | 11 | |
| Current EPS | $0.501 | $4.651 | $2.547 | |
| Month Ago EPS | $0.488 | $4.830 | $2.726 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.505 | $4.821 | $2.927 | |
| Year/Year Chg | (1,102%) | (165.2%) | (133.5%) | |
| Financials | SRPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,974 | $38 | 60% |
|
| Net Income (TTM) (Mil) | ($137) | ($44) | 9% |
|
| EPS (TTM) | ($1.316) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | $111 | ($31) | 53% |
|
| Net Cash Flow (TTM) (Mil) | $55 | $3 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $1,046 | $5 | 67% |
|
| Enterprise Value (Q1) (Mil) | $1,939 | $182 | 50% |
|
| Valuation | SRPT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.16 | 2.76 | 27% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SRPT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (18.0%) | 63.7% | 3% |
|
| Net Margin | (6.9%) | (70.3%) | 23% |
|
| ROA | (4.0%) | (50.0%) | 31% |
|
| ROE | (9.5%) | (57.5%) | 28% |
|
| Liabilities to Assets | 52.1% | 30.3% | 45% |
|
| F-Score | 7 | 3 | 84% |
|
Sarepta Therapeutics, Inc. did not pass any screens on 8/6/2026.
